Nikita Shah
CIK: 0001738061
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Amneal Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (33 total)
- Aug 12, 2026AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct146.4K shares at avg. $17.51$2.6M - Mar 4, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct18K shares at avg. $13.30$239K - Mar 4, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct35.9K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct11.8K shares at avg. $13.31$157K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct23.5K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct23K shares at avg. $13.31$306K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct45.9K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct36.2K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct18.5K shares at avg. $13.31$246K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct183.9K shares at avg. $13.31$2.4M - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct367K shares- - Mar 2, 2026AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectPerformance-Based Restricted Stock Units
65.4K shares- - Mar 2, 2026AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
65.4K shares- - Nov 12, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct36.3K shares at avg. $2.75$100K - Nov 12, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct95.5K shares at avg. $2.75$263K - Nov 12, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct131.9K shares at avg. $11.92$1.6M - Aug 25, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct6.3K shares at avg. $9.50$60K - Aug 22, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct114.5K shares at avg. $9.66$1.1M - Aug 14, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct71.7K shares at avg. $9.29$666K - Aug 12, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $9.04$452K - May 16, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct49.1K shares at avg. $7.58$372K - Mar 4, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct35.9K shares- - Mar 4, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct18.4K shares at avg. $8.84$162K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct18.5K shares at avg. $8.76$162K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct45.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 146,403 | $17.51 | $2,563,517 | Direct |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 17,976 | $13.30 | $239,081 | Direct |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 35,880 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 11,796 | $13.31 | $157,005 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 23,544 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 22,982 | $13.31 | $305,890 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 45,871 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 36,232 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 18,502 | $13.31 | $246,262 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 183,853 | $13.31 | $2,447,083 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 366,972 | - | $0 | Direct |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Performance-Based Restricted Stock Units | 65,359 | - | - | Direct |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 65,359 | - | - | Direct |
| Nov 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 36,331 | $2.75 | $99,910 | Direct |
| Nov 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 95,525 | $2.75 | $262,694 | Direct |
| Nov 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 131,856 | $11.92 | $1,571,724 | Direct |
| Aug 25, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 6,340 | $9.50 | $60,230 | Direct |
| Aug 22, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 114,492 | $9.66 | $1,105,993 | Direct |
| Aug 14, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 71,694 | $9.29 | $666,037 | Direct |
| Aug 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 50,000 | $9.04 | $452,000 | Direct |
| May 16, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 49,140 | $7.58 | $372,481 | Direct |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 35,879 | - | - | Direct |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 18,353 | $8.84 | $162,241 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 18,533 | $8.76 | $162,349 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 45,872 | - | - | Direct |
1-25 of 33 transactions
About Shah Nikita
Shah Nikita (SEC CIK 0001738061) files insider reports with the SEC as Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX).
Signal8 holds 10 ownership filings by Shah Nikita, all Form 4s, filed between Mar 4, 2025 and Aug 13, 2026. Those filings report 33 transactions, from Mar 1, 2025 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shah Nikita's filings is in BRIDGEWATER, NJ.
Recent filings by Shah Nikita
- Aug 12, 2026: Open-market sale of AMRX shares (Form 4, code S).
- Mar 4, 2026: Tax withholding of AMRX shares (Form 4, code F).
- Mar 4, 2026: Option exercise of AMRX shares (Form 4, code M).
- Mar 3, 2026: Tax withholding of AMRX shares (Form 4, code F).
- Mar 3, 2026: Option exercise of AMRX shares (Form 4, code M).
Other insiders filing for Amneal Pharmaceuticals, Inc. (AMRX)
- BUCHI J KEVIN, Director
- BOYER ANDREW S, Executive Vice President
- Kiely John, Director
- Daly Jason B., EVP, Chief Legal Officer
- Patel Tushar Bhikhubhai, 10% Owner
- Patel Chintu, Co-CEO